C F Friedman1,2, A Snyder1,2. Show Affiliations » 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. 2. Weill Cornell Medical College, New York, USA.
Abstract
Mesh: See more » Antibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/immunologyAntibodies, Monoclonal/therapeutic useAntineoplastic Agents, Immunological/adverse effectsAntineoplastic Agents, Immunological/immunologyAntineoplastic Agents, Immunological/therapeutic useB7-H1 Antigen/antagonists & inhibitorsB7-H1 Antigen/immunologyCTLA-4 Antigen/antagonists & inhibitorsCTLA-4 Antigen/immunologyHumansImmune System Diseases/chemically inducedImmune System Diseases/immunologyImmunotherapy/adverse effectsImmunotherapy/methodsNeoplasms/drug therapyNeoplasms/immunologyProgrammed Cell Death 1 Receptor/antagonists & inhibitorsProgrammed Cell Death 1 Receptor/immunology
Substances: See more » Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 Receptor
Year: 2017 PMID: 27993802 DOI: 10.1093/annonc/mdw658
Source DB: PubMed Journal: Ann Oncol ISSN: 0923-7534 Impact factor: 32.976